東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Formulating poorly water soluble drugs

Williams, Robert O.

FindBook

Google Book

Amazon

博客來

Formulating poorly water soluble drugs

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Formulating poorly water soluble drugs/ edited by Robert O. Williams III, Alan B. Watts, Dave A. Miller.
其他作者:	Williams, Robert O.
出版者:	Cham :Springer International Publishing : : 2016.,
面頁冊數:	xiv, 779 p. :ill., digital ;24 cm.
內容註:	Route-Specific Challenges in Delivery of Poorly Water Soluble Drugs -- Optimizing the Formulation of Poorly Water Soluble Drugs -- Solid-State Techniques for Improving Solubility -- Mechanical Particle Size Reduction Techniques -- Solubilized Formulations -- Injectable Formulations of Poorly Water Soluble Drugs -- Design and Development of Self-Emulsifying Lipid Formulations for Improving Oral Bioavailability of Poorly Water-Soluble and Lipophilic Drugs -- Structured Development Approach for Amorphous Systems -- Melt Extrusion -- Spray Drying Technology -- Pharmaceutical Cryogenic Technologies -- Precipitation Technologies for Nanoparticle Production -- Emerging Technologies to Increase the Bioavailability of Poorly Water Soluble Drugs -- Regulatory Considerations for Development and Commercialization of Poorly Water Soluble Drugs.
Contained By:	Springer eBooks
標題:	Drug development. -
電子資源:	http://dx.doi.org/10.1007/978-3-319-42609-9
ISBN:	9783319426099

Formulating poorly water soluble drugs
Formulating poorly water soluble drugs[electronic resource] /edited by Robert O. Williams III, Alan B. Watts, Dave A. Miller. - 2nd ed. - Cham :Springer International Publishing :2016. - xiv, 779 p. :ill., digital ;24 cm. - AAPS advances in the pharmaceutical sciences series,v.222210-7371 ;. - AAPS advances in the pharmaceutical sciences series ;v.22..

Route-Specific Challenges in Delivery of Poorly Water Soluble Drugs -- Optimizing the Formulation of Poorly Water Soluble Drugs -- Solid-State Techniques for Improving Solubility -- Mechanical Particle Size Reduction Techniques -- Solubilized Formulations -- Injectable Formulations of Poorly Water Soluble Drugs -- Design and Development of Self-Emulsifying Lipid Formulations for Improving Oral Bioavailability of Poorly Water-Soluble and Lipophilic Drugs -- Structured Development Approach for Amorphous Systems -- Melt Extrusion -- Spray Drying Technology -- Pharmaceutical Cryogenic Technologies -- Precipitation Technologies for Nanoparticle Production -- Emerging Technologies to Increase the Bioavailability of Poorly Water Soluble Drugs -- Regulatory Considerations for Development and Commercialization of Poorly Water Soluble Drugs.

The objective of this volume is to consolidate within a single text the most current knowledge, practical methods, and regulatory considerations pertaining to formulations development with poorly water-soluble molecules. A pharmaceutical scientist's approach toward solubility enhancement of a poorly water-soluble molecule typically includes detailed characterization of the compound's physiochemical properties, solid-state modifications, advanced formulation design, non-conventional process technologies, advanced analytical characterization, and specialized product performance analysis techniques. The scientist must also be aware of the unique regulatory considerations pertaining to the non-conventional approaches often utilized for poorly water-soluble drugs. One faced with the challenge of developing a drug product from a poorly soluble compound must possess at minimum a working knowledge of each of the abovementioned facets and detailed knowledge of most. In light of the magnitude of the growing solubility problem to drug development, this is a significant burden especially when considering that knowledge in most of these areas is relatively new and continues to develop.

ISBN: 9783319426099

Standard No.: 10.1007/978-3-319-42609-9doiSubjects--Topical Terms:

716904
Drug development.

LC Class. No.: RM301.25 / .F67 2016

Dewey Class. No.: 615.19

Formulating poorly water soluble drugs
LDR:03127nmm a2200337 a 4500 001 2082380
003 DE-He213
005 20161216102322.0
006 m d
007 cr nn 008maaau
008 170717s2016 gw s 0 eng d
020 $a 9783319426099 $q (electronic bk.)
020 $a 9783319426075 $q (paper)
024 7 $a 10.1007/978-3-319-42609-9 $2 doi
035 $a 978-3-319-42609-9
040 $a GP $c GP
041 0 $a eng
050 4 $a RM301.25 $b .F67 2016
072 7 $a TDCW $2 bicssc
072 7 $a MED072000 $2 bisacsh
082 0 4 $a 615.19 $2 23
090 $a RM301.25 $b .F726 2016
245 0 0 $a Formulating poorly water soluble drugs $h [electronic resource] / $c edited by Robert O. Williams III, Alan B. Watts, Dave A. Miller.
250 $a 2nd ed.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2016.
300 $a xiv, 779 p. : $b ill., digital ; $c 24 cm.
490 1 $a AAPS advances in the pharmaceutical sciences series, $x 2210-7371 ; $v v.22
505 0 $a Route-Specific Challenges in Delivery of Poorly Water Soluble Drugs -- Optimizing the Formulation of Poorly Water Soluble Drugs -- Solid-State Techniques for Improving Solubility -- Mechanical Particle Size Reduction Techniques -- Solubilized Formulations -- Injectable Formulations of Poorly Water Soluble Drugs -- Design and Development of Self-Emulsifying Lipid Formulations for Improving Oral Bioavailability of Poorly Water-Soluble and Lipophilic Drugs -- Structured Development Approach for Amorphous Systems -- Melt Extrusion -- Spray Drying Technology -- Pharmaceutical Cryogenic Technologies -- Precipitation Technologies for Nanoparticle Production -- Emerging Technologies to Increase the Bioavailability of Poorly Water Soluble Drugs -- Regulatory Considerations for Development and Commercialization of Poorly Water Soluble Drugs.
520 $a The objective of this volume is to consolidate within a single text the most current knowledge, practical methods, and regulatory considerations pertaining to formulations development with poorly water-soluble molecules. A pharmaceutical scientist's approach toward solubility enhancement of a poorly water-soluble molecule typically includes detailed characterization of the compound's physiochemical properties, solid-state modifications, advanced formulation design, non-conventional process technologies, advanced analytical characterization, and specialized product performance analysis techniques. The scientist must also be aware of the unique regulatory considerations pertaining to the non-conventional approaches often utilized for poorly water-soluble drugs. One faced with the challenge of developing a drug product from a poorly soluble compound must possess at minimum a working knowledge of each of the abovementioned facets and detailed knowledge of most. In light of the magnitude of the growing solubility problem to drug development, this is a significant burden especially when considering that knowledge in most of these areas is relatively new and continues to develop.
650 0 $a Drug development. $3 716904
650 0 $a Drugs $x Design. $3 664528
650 1 4 $a Biomedicine. $3 890831
650 2 4 $a Pharmaceutical Sciences/Technology. $3 1001579
700 1 $a Williams, Robert O. $3 1566953
700 1 $a Watts, Alan B. $3 1566954
700 1 $a Miller, Dave A. $3 1566955
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer eBooks
830 0 $a AAPS advances in the pharmaceutical sciences series ; $v v.22. $3 3205719
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-42609-9
950 $a Biomedical and Life Sciences (Springer-11642)